The Proactive Patient: 10 Questions for Your Cancer Care Team
Ten Questions Every Patient Should be Asking
Clinician's View: Making Survival a Blessing, Not a Burden
More and more deadly diseases are slowly being transformed into chronic conditions. This is especially true of cancer.
The Downside to Beating the Odds
By now, I am supposed to be dead.
Novel Agents in the Management of Castration-Resistant Metastatic Prostate Cancer
The Prostate Cancer Clinical States model was first proposed by Scher and colleagues nearly 10 years ago.
Biomarkers in Ovarian Cancer: Early Detection and Chemoresistance
Worldwide, there are ~204,000 new cases of ovarian cancer each year, accounting for 4% of cancers diagnosed in women.
Maintenance Therapy in Advanced Non-Small Cell Lung Cancer: Before We Accept This Treatment Paradigm, Let's Critically Evaluate and Interpret the Data
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality in the United States.
Managing the Side Effects of Androgen-Deprivation Therapy
Androgen-deprivation therapy (ADT) is a widely accepted treatment for men with advanced or metastatic prostate cancer.
Summer FDA Updates
FDA updates from the summer of 2010
Tasigna Moves to the Front-Line in CML
The FDA approved Tasigna (nilotinib) as a first-line treatment for patients with newly diagnosed Philadelphia- chromosome positive (Ph ) chronic myeloid leukemia (CML), the first new drug approved for this indication in nearly a decade.
Jevtana Approved for Advanced Prostate Cancer
The FDA approved the injectable drug Jevtana (cabazitaxel), a microtubule inhibitor, in combination with prednisone as a second-line therapy for men with advanced castrate-resistant prostate cancer
Afinitor Active in Pancreatic NET
In the RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors) phase III study involving patients with pancreatic neuroendocrine tumors (NET)
Truly Community-Based Oncology
As 2010 has rolled along, the Intellisphere Oncology Specialty Group has aimed to uphold its mission of Bringing the Oncology Community Together.
What to Look for in this Issue
The landscape for managing prostate cancer is changing rapidly. In recent months, we have seen two new drugs approved for hormone refractory advanced disease
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512